Cramer's 'Mad Money' Recap: Just Do It Like Nike

Trade Crocs short term, Cramer advised. He said he would own it for the next quarter or two, even though he believes that "it's a dead-end business" long-term.

Crocs has had a "big run" for the last couple of weeks and 36% of its float is being sold short, Cramer said. Even though the shorts are not wrong, as always, "they are way too early," he said, adding that he believes the run-up in the stock should cause a short-squeeze and send the stock higher.

"If you want to invest in the next Nike, you need Under Armour," Cramer told viewers. "If you want to trade, as long as you have an exit strategy, Crocs is two thumbs up."

Cramer welcomed Robert Hugin, Celgene (CELG Quote) president and COO -- and Darden Business School alumnus -- to the show.

"It's great to be back at Darden," Hugin said to audience cheers.

Cramer asked Hugin his thoughts regarding criticism that Celgene is stalled and the best is behind the company.

"They're going to be sadly mistaken," Hugin responded. "We had a great performance, but the best is yet to come."

He called Celgene's Revlimid drug "a breakthrough therapy" that makes a difference in tens of thousands of cancer patients' lives. "The future is very bright for Revlimid," Hugin said.